Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Mini

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
"Pharmacogenetics of Cancer" - <i>Cancer Drug Resistance</i> special issueEnrico Mini, Stefania Nobili
Journal of Personalized Medicine|March 25, 2022
Special Issue: "Gastrointestinal Cancers and Personalized Medicine"Stefania Nobili, Enrico Mini
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|March 31, 2012
Pharmacogenetics: implementing personalized medicineEnrico Mini, Stefania Nobili
Clinical Pharmacokinetics|June 27, 2002
Clinical pharmacokinetics of depot leuprorelinPiero Periti, Teresita Mazzei, Enrico Mini
Journal of Chemotherapy (Florence, Italy)|August 22, 2019
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical developmentGiandomenico Roviello, Stefania Nobili, Enrico Mini
Lancet (London, England)|January 14, 2020
Perioperative chemotherapy for gastric cancer in FLOT4Giandomenico Roviello, Franco Roviello, Enrico Mini
Frontiers in Oncology|June 2, 2015
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issuesChiara Riganti, Enrico Mini, Stefania Nobili
Annals of Translational Medicine|October 29, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?Giulia Di Pierro, Enrico Mini, Giandomenico Roviello
Medicinal Research Reviews|March 5, 2011
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expressionStefania Nobili, Ida Landini, Teresita Mazzei, et al.
Therapeutic Advances in Medical Oncology|August 21, 2019
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?Giandomenico Roviello, Silvia Paola Corona, Gabriella Nesi, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
"Pharmacogenetics of Cancer" - <i>Cancer Drug Resistance</i> special issueEnrico Mini, Stefania Nobili
Journal of Personalized Medicine|March 25, 2022
Special Issue: "Gastrointestinal Cancers and Personalized Medicine"Stefania Nobili, Enrico Mini
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|March 31, 2012
Pharmacogenetics: implementing personalized medicineEnrico Mini, Stefania Nobili
Clinical Pharmacokinetics|June 27, 2002
Clinical pharmacokinetics of depot leuprorelinPiero Periti, Teresita Mazzei, Enrico Mini
Journal of Chemotherapy (Florence, Italy)|August 22, 2019
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical developmentGiandomenico Roviello, Stefania Nobili, Enrico Mini
Lancet (London, England)|January 14, 2020
Perioperative chemotherapy for gastric cancer in FLOT4Giandomenico Roviello, Franco Roviello, Enrico Mini
Frontiers in Oncology|June 2, 2015
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issuesChiara Riganti, Enrico Mini, Stefania Nobili
Annals of Translational Medicine|October 29, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?Giulia Di Pierro, Enrico Mini, Giandomenico Roviello
Medicinal Research Reviews|March 5, 2011
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expressionStefania Nobili, Ida Landini, Teresita Mazzei, et al.
Therapeutic Advances in Medical Oncology|August 21, 2019
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?Giandomenico Roviello, Silvia Paola Corona, Gabriella Nesi, et al.
Pageof 14